See more : Primeserv Group Limited (PMV.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Pacira BioSciences, Inc. (PCRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pacira BioSciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Turaco Gold Limited (TCG.AX) Income Statement Analysis – Financial Results
- Unitronix Corporation (UTRX) Income Statement Analysis – Financial Results
- TRACON Pharmaceuticals, Inc. (TCON) Income Statement Analysis – Financial Results
- CapitaLand Ascott Trust (ATTRF) Income Statement Analysis – Financial Results
- VITZROCELL Co.,Ltd. (082920.KQ) Income Statement Analysis – Financial Results
Pacira BioSciences, Inc. (PCRX)
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 674.98M | 666.82M | 541.53M | 420.83M | 421.03M | 337.28M | 286.63M | 276.37M | 249.00M | 197.67M | 85.55M | 39.08M | 15.69M | 14.56M | 15.01M | 13.93M |
| Cost of Revenue | 184.67M | 199.30M | 140.26M | 117.33M | 106.71M | 86.85M | 87.92M | 110.10M | 71.84M | 77.44M | 54.77M | 32.14M | 16.74M | 12.28M | 12.30M | 17.46M |
| Gross Profit | 490.31M | 467.53M | 401.28M | 303.50M | 314.31M | 250.43M | 198.72M | 166.27M | 177.16M | 120.23M | 30.78M | 6.95M | -1.05M | 2.29M | 2.71M | -3.54M |
| Gross Profit Ratio | 72.64% | 70.11% | 74.10% | 72.12% | 74.65% | 74.25% | 69.33% | 60.16% | 71.15% | 60.82% | 35.98% | 17.77% | -6.69% | 15.70% | 18.03% | -25.41% |
| Research & Development | 76.26M | 84.80M | 55.55M | 59.42M | 72.12M | 55.69M | 57.29M | 45.68M | 28.66M | 18.73M | 21.56M | 9.94M | 14.87M | 18.63M | 26.23M | 33.21M |
| General & Administrative | 116.40M | 109.52M | 88.32M | 74.83M | 71.12M | 70.16M | 66.69M | 63.40M | 61.31M | 41.65M | 20.96M | 15.97M | 20.16M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 153.04M | 145.00M | 111.02M | 118.68M | 129.66M | 107.11M | 94.80M | 89.22M | 77.73M | 65.01M | 41.55M | 30.33M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 269.44M | 254.52M | 199.35M | 193.52M | 200.78M | 177.27M | 161.49M | 152.61M | 139.04M | 106.66M | 62.51M | 46.31M | 20.16M | 6.03M | 5.02M | 8.61M |
| Other Expenses | 56.94M | 57.29M | 13.55M | 7.87M | 5.70M | -888.00K | 167.00K | -82.00K | -165.00K | -159.00K | -47.00K | -111.00K | 3.02M | 6.03M | 5.02M | 8.61M |
| Operating Expenses | 402.63M | 396.60M | 268.44M | 260.80M | 278.60M | 232.95M | 218.78M | 198.29M | 167.71M | 125.39M | 84.07M | 56.24M | 35.03M | 24.66M | 31.25M | 41.83M |
| Cost & Expenses | 587.30M | 595.90M | 408.70M | 378.13M | 385.32M | 319.80M | 306.70M | 308.40M | 239.54M | 202.83M | 138.84M | 88.38M | 51.77M | 36.93M | 43.55M | 59.29M |
| Interest Income | 11.44M | 4.54M | 896.00K | 4.63M | 7.38M | 6.50M | 4.08M | 1.32M | 678.00K | 382.00K | 259.00K | 275.00K | 255.00K | 146.00K | 77.00K | 235.00K |
| Interest Expense | 20.31M | 39.98M | 31.75M | 25.67M | 23.63M | 21.95M | 18.05M | 7.06M | 7.73M | 8.28M | 7.25M | 1.81M | 4.78M | 4.89M | 3.60M | 3.49M |
| Depreciation & Amortization | 75.57M | 91.50M | 28.55M | 19.91M | 19.58M | 13.17M | 13.83M | 12.92M | 11.48M | 10.04M | 5.75M | 5.65M | 4.31M | 4.25M | 4.43M | 3.83M |
| EBITDA | 157.58M | 144.78M | 118.47M | 71.42M | 55.29M | 33.06M | -10.59M | -17.86M | 21.39M | 5.09M | -50.73M | -44.55M | -34.23M | -19.12M | -24.12M | -41.53M |
| EBITDA Ratio | 23.35% | 18.22% | 26.71% | 15.89% | 10.41% | 6.85% | -5.52% | -11.14% | 4.00% | -2.50% | -55.32% | -125.71% | -185.14% | -124.20% | -163.15% | -296.65% |
| Operating Income | 87.68M | 60.02M | 131.07M | 46.35M | 38.11M | 15.92M | -24.94M | -32.02M | 9.46M | -5.17M | -53.29M | -49.30M | -39.10M | -22.37M | -28.55M | -45.36M |
| Operating Income Ratio | 12.99% | 9.00% | 24.20% | 11.01% | 9.05% | 4.72% | -8.70% | -11.59% | 3.80% | -2.61% | -62.29% | -126.13% | -249.23% | -153.63% | -190.24% | -325.77% |
| Total Other Income/Expenses | -25.97M | -46.72M | -33.52M | -26.26M | -26.66M | -16.34M | -17.53M | -5.82M | -7.34M | -8.38M | -11.06M | -2.98M | -4.23M | -4.78M | -3.16M | 3.50M |
| Income Before Tax | 61.70M | 13.30M | 56.40M | 20.09M | -10.75M | -425.00K | -42.47M | -37.84M | 2.12M | -13.54M | -64.35M | -52.28M | -43.33M | -27.15M | -28.18M | -45.59M |
| Income Before Tax Ratio | 9.14% | 1.99% | 10.42% | 4.77% | -2.55% | -0.13% | -14.82% | -13.69% | 0.85% | -6.85% | -75.22% | -133.77% | -276.17% | -186.44% | -187.80% | -327.38% |
| Income Tax Expense | 19.75M | -2.61M | 14.42M | -125.43M | 268.00K | 46.00K | 140.00K | 105.00K | 264.00K | 173.00K | -442.00K | -3.95M | 7.25M | 4.78M | 3.16M | -3.50M |
| Net Income | 41.96M | 15.91M | 41.98M | 145.52M | -11.02M | -471.00K | -42.61M | -37.95M | 1.86M | -13.72M | -63.91M | -52.28M | -43.33M | -27.15M | -31.71M | -41.86M |
| Net Income Ratio | 6.22% | 2.39% | 7.75% | 34.58% | -2.62% | -0.14% | -14.87% | -13.73% | 0.75% | -6.94% | -74.70% | -133.77% | -276.17% | -186.44% | -211.30% | -300.62% |
| EPS | 0.91 | 0.35 | 0.95 | 3.41 | -0.27 | -0.01 | -1.07 | -1.02 | 0.05 | -0.39 | -1.93 | -1.72 | -2.64 | -1.58 | -55.32 | -79.23 |
| EPS Diluted | 0.81 | 0.34 | 0.92 | 3.33 | -0.27 | -0.01 | -1.07 | -1.02 | 0.04 | -0.39 | -1.93 | -1.72 | -2.64 | -1.58 | -55.32 | -79.23 |
| Weighted Avg Shares Out | 46.22M | 45.52M | 44.26M | 42.67M | 41.51M | 40.91M | 39.81M | 37.20M | 36.54M | 35.17M | 33.11M | 30.33M | 16.44M | 17.23M | 573.12K | 528.36K |
| Weighted Avg Shares Out (Dil) | 51.98M | 46.54M | 45.63M | 43.68M | 41.51M | 40.91M | 39.81M | 37.24M | 41.30M | 35.30M | 33.18M | 30.33M | 16.44M | 17.23M | 573.12K | 528.36K |
Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated
Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales.
Pacira (PCRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Pacira (PCRX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Pacira (PCRX) Misses Q3 Earnings and Revenue Estimates
Pacira (PCRX) came out with quarterly earnings of $0.72 per share, missing the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.64 per share a year ago.
Pacira BioSciences Reports Third Quarter 2023 Financial Results
-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 --
Pacira (PCRX) to Report Q3 Results: Wall Street Expects Earnings Growth
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023
TAMPA, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday November 2, 2023. Following the release, the company...
American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.
SCHAUMBERG, Ill. and TAMPA, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- The American Society of Anesthesiologists (ASA) today announced Pacira BioSciences, Inc. (Nasdaq: PCRX) has joined ASA's Industry Supporter Program to support the Society's more than 56,000 physician anesthesiologist members...
Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors
-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health...
American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care
SCHAUMBURG, Ill. and TAMPA, Fla., Oct. 02, 2023 (GLOBE NEWSWIRE) -- The American Society of Anesthesiologists (ASA) and Pacira BioSciences, Inc. (Nasdaq: PCRX), today announced a new grant of $2.5 million, by Pacira to the ASA Charitable Foundation, to advance...
Pacira BioSciences Announces Leadership Succession Plan
David Stack to Retire as Chairman and CEO Once Successor is Appointed Board Has Initiated Search for Successor TAMPA, Fla., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain...
Source: https://incomestatements.info
Category: Stock Reports